Meanwhile, other pyroptosis markers such as GSDED, CASP1, GSDMC, and GSDMA also have higher expression level in GBM (Supplementary Fig. 1A), implying that inducing pyroptosis can be acted as an effective approach for GBM treatment, but also implying that pyroptosis may be related to the inhibitory tumor immune microenvironment (TIME) in GBM. The gene discussed is GSDMA; the disease is glioblastoma.